|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
To identify biologic and outcome differences between double hormone receptor (HR)-positive (dHR<sup>+</sup>, estrogen receptor (ER)<sup>+</sup>/progesterone receptor [PgR<sup>+</sup>]) and single HR-positive (sHR<sup>+</sup>, either ER<sup>+</sup>/PgR<sup>-</sup> or ER<sup>-</sup>/PgR<sup>+</sup>) breast cancer; and to explore whether hormone therapy (HT) response in HER2-negative breast cancer correlates with HR status.
|
31551181 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
According to the 2017 St Gallen surrogate definitions of the intrinsic subtypes, Ki67, progesterone receptor (PR) and Nottingham histological grade (NHG) are used for prognostic classification of estrogen receptor (ER) positive/HER2-negative breast cancer into luminal A- or luminal B-like.
|
30796653 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We provide clinical evidence that genetic alteration of the TP53 gene and dysregulated glucose metabolism partly involve low PR expression in ER-positive and HER2-negative breast cancer.
|
30407916 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
|
30080878 |
2018 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
|
30613307 |
2018 |
|
HER2-negative breast cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It may be more clinically relevant to define triple-negative breast cancer as HER2-negative breast cancer with <10%, rather than <1%, of ER and/or progesterone receptor expression.
|
28961844 |
2017 |
|
HER2-negative breast cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer.
|
28756019 |
2017 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human triple (estrogen receptor, progesterone receptor, and HER2)-negative breast cancer (TNBC) cell lines were treated with TRAIL receptor agonists (monoclonal antibodies or TRAIL peptide), metformin, or the combination.
|
28324269 |
2017 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this randomized, double-blind, placebo-controlled phase III trial, we assessed first- or second-line capecitabine with sorafenib or placebo in patients with locally advanced/metastatic HER2-negative breast cancer resistant to a taxane and anthracycline and with known estrogen/progesterone receptor status.
|
28830796 |
2017 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The triple negative [estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (Her2)] breast cancer cell line MDA-MB-231 and ER/PR/HER-2-positive breast cancer cell line MCF-7 were cultured, transfected with Notch1-siRNA-overexpression plasmid and blank plasmid, and treated with different concentrations of paclitaxel, and then the cell proliferation activity and apoptosis rate as well as the mRNA expression of Caspase-3, Caspase-9 and Bcl-2 were determined.
|
28237486 |
2017 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Six hundred seventy-one patients (≥35 years of age, pT1-2, pN0-1) with ER-positive/HER2-negative breast cancer and complete data for PgR, Ki-67, G, lymph node status, tumor size, age, and distant disease-free survival (DDFS; median follow-up 9.2 years) were included.
|
27762648 |
2017 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
|
25600243 |
2015 |
|
HER2-negative breast cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The associations between the 21-gene recurrence score (RS), AR, grade, mitotic score, Ki-67 and estrogen receptor (ER) and progesterone receptor (PgR) expression were explored in sequential women with lymph node-negative, ER-positive and HER2-negative breast cancer.
|
26076967 |
2015 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we investigated matrix hyaluronan (HA)-CD44 (a primary HA receptor) interaction with c-Jun N-Terminal Kinase (JNK)/c-Jun signaling in MDA-MB-468 breast cancer cells [a triple-negative (estrogen receptor-negative/progesterone receptor-negative/HER2-negative) breast cancer cell line].
|
24606718 |
2014 |
|
HER2-negative breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Variants from 19p13.1 were not associated with breast cancer overall or with ER-positive breast cancer but were significantly associated with ER-negative breast cancer risk [rs8170 OR, 1.10; 95% confidence interval (CI), 1.05-1.15; P = 3.49 × 10(-5)] and triple-negative (ER-, PR-, and HER2-negative) breast cancer (rs8170: OR, 1.22; 95% CI, 1.13-1.31; P = 2.22 × 10(-7)).
|
22331459 |
2012 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The variant was also significantly associated with triple-negative (ER-negative, progesterone receptor (PR)-negative and human epidermal growth factor-2 (HER2)-negative) breast cancer (OR = 1.25, P = 1.1 × 10(-9)), particularly in younger women (<50 years of age) (OR = 1.48, P = 1.9 × 10(-9)).
|
22037553 |
2011 |